Glycominds IBDX® panel is a series of CE MARK IVD kits that help physicians identify patients who have Crohn’s Disease and which of the patients are at higher risk for bowel damage and surgery. These patients can be candidates for “top down” therapy with biologics. IBDX® is the most validated and cost-effective serological panel to aid in the deferential diagnosis of IBD vs. non-IBD and for CD vs. UC, as well as for predicting the probability of Crohn's Disease progression.
IBDX kits achieved CE MARK regulation.
All kits are Quick and Easy to use with short incubation times and ready-to-use reagents. Also, all IBDX kits have break-a-well strips allowing high flexibility and economic use.
For additional information visit www.ibdx.net
Improve Sensitivity and Specificity
The IBDX biomarkers panel: gASCA, ALCA, ACCA, AMCA, Anti-L and Anti-C were analyzed on over 7,500 patients' samples in multiple independent clinical studies around the globe, including: Australia, Belgium, Canada, China, Czech Republic ,France, Germany, Greece, Hungry, Italy, Israel, Poland, Saudi Arabia and the U.S. – which makes it the most validated panel for IBD.
Studies showed up to 97% specificity in differentiating CD from US patients and up to 70% sensitivity in identifying patients with UC. It has been reported up to 85.5% sensitivity in identifying patients with CD using multiple markers and up to 56.4% sensitivity in identifying CD patients who are sero-negative to anti-Saccharomyces Cerevisiae antibody (ASCA).
Crohn's Disease Progression
Three Crohn’s disease prognostic levels for disease severity are provided, allowing for improved treatment decisions.
Patients positive for two or more IBDX Antibodies:
- 70% are likely to have complicated disease
- 60% are likely to require abdominal surgery
Patients positive for three or more IBDX Antibodies:
- 90% are likely to have complicated disease
- 80% are likely to require abdominal surgery
Predict Disease Outcome
IBDX antibodies were shown to be able to predict patients who are at a higher risk for first complication and abdominal surgery (HR: 2.8 to 3.1, p<0.007).
Inflammatory Bowel Disease diagnosis and Crohn’s disease risk levels and prognostic information were validated prospectively in adults and children
Number of positive serological markers
adopted from Reider et. al. 2010 IBD 16 (2) 263-274
adopted from Dotan et. al. 2006 Gastroenterology 16 (2) 263-274
adopted from Reider et. al. 2008 DDW oral presentation
We are expanding rapidly around the globe
Contact us to learn how you can offer the IBDK kits in your country